
Paul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.

Your AI-Trained Oncology Knowledge Connection!


Paul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.

Paul K. Paik, MD, discusses the benefits to using liquid biopsy compared to a tissue biopsy, particularly in the phase II VISION trial in which patients with non–small cell lung cancer harboring MET alterations were treated with tepotinib. Patients were divided into 2 cohorts based on whether they were enrolled with either a liquid biopsy or tumor biopsy.

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent chemotherapy and immunotherapy advances in the treatment of squamous cell lung cancer.

Published: January 13th 2018 | Updated:

Published: June 20th 2019 | Updated: